NCT05967299View on ClinicalTrials.gov

Study of Intravenous ZMA001 in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

September 1, 2027

Study Completion Date

November 30, 2027

Conditions
Pulmonary Arterial Hypertension PAH
Interventions
OTHER

Placebo Cohort 1 (1.5 mg/kg/dose) only

30mg/ml Sucrose

DRUG

ZMA001 (BC-NKA-20008)

ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

Zymedi, Co., Ltd.

UNKNOWN

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH